ArticleJournal of experimental & clinical cancer research : CR2025
CC48 a new CB2R agonist/FAAH inhibitor dual drug blocks gastric cancer progression and overcomes paclitaxel resistance.
Annalisa Schirizzi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.